Ductus Arteriosus, Patent: all 146 studies

Page 2 of 2. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.SuspendedNCT02056223Phase 2/3
• Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm InfantsCompletedNCT02002741Phase 2/3
• The Preterm Infants' Paracetamol StudyCompletedNCT01938261Phase 2
• Long Term Results of 450 Percutaneous Closures of PDA in a Single CenterCompletedNCT01929733
• Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight InfantsCompletedNCT01758913Not applicable
• Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)CompletedNCT01630278Phase 3
• Packed Red Blood Cell Transfusion and Intestinal Blood Flow in Preterm NeonatesCompletedNCT01628133
• Heart Cycle PrestudyCompletedNCT01627457Not applicable
• Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus ArteriosusCompletedNCT01593163Phase 3
• Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm InfantsStatus unknownNCT01544972Phase 4
• Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled TrialCompletedNCT01536158Phase 4
• Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)CompletedNCT01511887Not applicable
• Do Elevated BNP Levels Predict Hemodynamically Significant PDAsCompletedNCT01497054
• Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus ArteriosusCompletedNCT01479218Not applicable
• Ascorbyl Peroxide Association With Bronchopulmonary DysplasiaCompletedNCT01439295
• Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm InfantsCompletedNCT01428180
• Paracetamol and Patent Ductus Arteriosus (PDA)Status unknownNCT01291654Phase 2
• Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW InfantsCompletedNCT01261117Not applicable
• Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus ArteriousCompletedNCT01251939
• High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm InfantCompletedNCT01243996Phase 2/3
• Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)WithdrawnNCT01070745Phase 2
• Timing of Closure of Patent Foramen Ovale Following BirthStatus unknownNCT01032785
• Patent Ductus Arteriosus (PDA) Screening TrialCompletedNCT01031316Not applicable
• Impact of Maternal-infant Therapeutics on Safety, Mortality, and DisabilityWithdrawnNCT01028183
• Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure RatesTerminatedNCT00961753Phase 4
• NIT-OCCLUD PDA Phase II Sentinel TrialCompletedNCT00828334Not applicable
• Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) InfantsCompletedNCT00799123
• Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm InfantsCompletedNCT00795990
• An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm InfantsTerminatedNCT00750581Phase 2/3
• Feeding During Ibuprofen or Indomethacin Treatment of Preterm InfantsCompletedNCT00728117Not applicable
• Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm BabiesCompletedNCT00725647
• Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight InfantsCompletedNCT00642330Phase 4
• Treating the Resistant Patent Ductus Arteriosus (PDA)Status unknownNCT00616382Phase 2
• Brain, Gut and Kidney Blood Flow During Medical Closure of PDAWithdrawnNCT00554307
• Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 WeeksCompletedNCT00528736
• The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature InfantsCompletedNCT00500305Not applicable
• Ibuprofen vs. Continuous Indomethacin in the Treatment of PDACompletedNCT00485160Phase 3
• Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature BabiesWithdrawnNCT00470743Phase 4
• Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDACompletedNCT00440804Phase 3
• New Management Strategy of PDA for VLBW Preterm InfantsTerminatedNCT00239512Not applicable
• Ibuprofen and Renal Function in Premature InfantsCompletedNCT00217191Phase 4
• Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus ArteriosusCompletedNCT00187447Phase 2
• Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm InfantsCompletedNCT00162903
• Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)CompletedNCT00009646Phase 3
• Reproduction and Survival After Cardiac Defect RepairCompletedNCT00005190
• Management of Patent Ductus in Premature InfantsCompletedNCT00000494Phase 3

← Ductus Arteriosus, Patent overview